SHEnB ‘PlaDuo’ approved by U.S. FDA, Open the way to export to the US
SHEnB ‘PlaDuo’ approved by U.S. FDA, Open the way to export to the US
  • Philip Choi
  • 승인 2021.06.09 14:13
  • 댓글 0
이 기사를 공유합니다

SHEnB started to export PlaDuo to the U.S market on March 8, about 3 months after it acquired FDA approval on December 15, 2020.

PlaDuo is a medical device developed by SHEnB, a Korean medical device manufacturer, and it is the world's first dual plasma device using two types of plasma. PlaDuo is designed to implement dual plasma of argon and nitrogen so that it can treat skin lesions and it is known for its anti-bacterial effect.

Pladuo, developed after four years of development, was the first in Korea to be licensed as plasma using gas, and it’s also the first case in Korea to export to the United States among devices in the same field. Sunyoung KANG, CEO of SHEnB, a manufacturer of PlaDuo, said, “I am happy to export it eventually in spite of many difficulties in proceeding with the FDA approval for PlaDuo. We were able to export it to the U.S in such a short time due to the constant inquiries and interest in PlaDuo from the US. This achievement was possible thanks to the stabilization of plasma energy, steady clinical data, and the efforts of R&D employees. As PlaDuo is being exported to the US for the first time, we have high expectations and concerns. We hope that it will be widely known as good treatment among many patients in the US, as well as in Korea.”

Sunyoung KANG, CEO of SHNB, and Changwon Choi, chief developer of PlaDuo (left), are standing in front of PlaDuo.
Sunyoung KANG, CEO of SHEnB, and Changwon Choi, chief developer of PlaDuo (left), are standing in front of PlaDuo.

In addition, Changwon Choi, chief developer of PlaDuo, said, “As it’s been painstakingly developed for a long time, it’s very meaningful that it will be exported to the US with the U.S. FDA approval. We will continue to work hard to develop better products and repay our customers with good products.”

PlaDuo has a total of 4 papers (preclinical, acne, melasma, tinea pedis) including SCI and clinical papers. In 2020, it was selected as a next-generation world-class product certified by KOTRA.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

Medical Aesthetic Curation
헤드라인
  • 서울특별시 서초구 강남대로 369, 12-1584(서초동)
  • 대표전화 : 070-4064-1064
  • 팩스 : 0504-130-2015
  • 사업자 등록번호 : 840-88-00935
  • 청소년보호책임자 : 최성필
  • 회사명 : (주)미로아이앤씨(MIRO I&C)
  • 제호 : MedicalAestheticNews
  • 등록번호 : 서울 아 05071
  • 등록일 : 2018-04-03
  • 발행일 : 2018-05-07
  • 발행인 : 임노정
  • 편집인 : 최성필
  • MedicalAestheticNews의 모든 콘텐츠(영상, 기사, 사진)는 저작권법의 보호를 받는바, 무단 전재와 복사, 배포 등을 금합니다.
  • Copyright © 2021 MedicalAestheticNews. All rights reserved. mail to news@miroinc.co.kr
ND소프트